Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield
Profit from AI driven tools that increase lead conversion rates and product sales  - Blockchain Investments for Maximum Yield

Profit from AI driven tools that increase lead conversion rates and product sales - Blockchain Investments for Maximum Yield

₹1887

Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Make your ₹500 grow rapidly with AI-backed investments.

quantity
Add to Wishlist
Product Description

Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Make your ₹500 grow rapidly with AI-backed investments.

Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Make your ₹500 grow rapidly with AI-backed investments.Serum Institute of India (SII) has entered into an exclusive licence agreement with French speciality vaccine company Valneva SE to manufacture and sell Valneva’s chikungunya vaccine in India and the rest of Asia.Valneva’s chikungunya vaccine is the world’s first and only licensed vaccine.

It is currently approved in the US, Europe, and Canada for adults.  Regulatory reviews are underway to expand it to children up to 12 years.Chikungunya virus is a mosquito-borne viral disease spread by the bites of infected Aedes mosquitoes.

It causes fever, severe joint and muscle pain, headache, nausea, fatigue, and rash.

Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Start with ₹500 and earn big! High returns, low risk, and consistent growth.The joint pain is often debilitating and can persist for weeks to years.Indiais currently enduring one of its worst chikungunya outbreaks.

Nearly 3,70,000 cases were confirmed in India between January 2019 and July 2024, and it was rapidly increasing due to the current outbreak.

Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Make your ₹500 grow rapidly with AI-backed investments.Both companies will work to bring the vaccine to the Indianmarketand some  Asian countries, after approval from local regulators.SII has committed to a priority supply of the chikungunya vaccine at an affordable price to publichealthmarkets in low- and middle-income countries (LMICs).Profit from AI driven tools that increase lead conversion rates and product sales ✌️【Investment Strategy】✌️Small investments, big profits. Join today and grow your wealth quickly and safely!

Related Products